Foley Partner Paul Broude authored an article titled “The IPO Window Is Opening” in the March 2010 issue of MX: Medtech Executive. Broude examines the reasons for a device company to consider an initial public offering for its growth plans, stating that 2010 may bring the promise of IPOs for medical device companies to fund clinical trials, regulatory approvals, and the protection of the company’s intellectual property. He adds that going public enables some medical device and life science companies to continue growing while creating an exit vehicle for management and other shareholders.
Author(s)
Related Insights
26 April 2024
Article
Increased Tariffs on Imports of Selected Products
As an additional measure to those taken last year, the Federal Government again modified the Law of General Import and Export Taxes (Ley de los Impuestos Generales de Importación y Exportación) in order to provide fair conditions to national industry and prevent bad practices in international trade, promoting the development of national industry and supporting the domestic market to balance the situation faced with the global market that has taken place as a consequence of the nearshoring phenomenon.
26 April 2024
Article
Non-Competes: What the FTC’s Rule May Mean for Health Care & Life Sciences Providers
On April 23, 2024, the U.S. Federal Trade Commission finalized a rule, by a vote of 3-2, abolishing the vast majority of employee covenants not to compete across the United States
03 May 2024
Events
Takeaways from the Trenches: the JetBlue/Spirit Merger Trial
Foley Partner Ben Dryden will moderate a panel for the ABA State Enforcement and the Mergers and Acquisitions Committees as they host a panel consisting of both enforcers and private practitioners, who will discuss the JetBlue/Spirit merger and what this decision may mean for the future of merger enforcement, including in the airline industry.